LongBio Pharma (Suzhou) Co., Ltd. Class H 1779

HKEX · Hong Kong SAR China · Health Technology

HKD 104.50-1.30 (-1.23%)

Market open· Oct 2, 2026, 1:57 AM UTC· HKD · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

LongBio Pharma (Suzhou) Co., Ltd. Class H 1779

HKEX · Hong Kong SAR China · Health Technology

HKD 104.50-1.30 (-1.23%)

Market open· Oct 2, 2026, 1:57 AM UTC· HKD · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

-20.71% · 6MFull-screen chart

Open HKD 100.00High HKD 104.50Low HKD 100.00Close HKD 104.50Volume 1.40K

Oct 2, 2026

Charts by TradingView Lightweight Charts

Key statistics

Previous close: HKD 105.80
Day range: HKD 100.00 – HKD 104.50
52-week range: HKD 72.65 – HKD 165.90
Volume: 1.40K
Market cap: HKD 8.07B
Avg. volume (1Y): 222.99K

Performance

1 week

-11.39%

1 month

-12.99%

3 months

-0.09%

6 months

-19.73%

Year to date

-19.73%

1 year

-19.73%

Total return, dividends included.

Company profile

Sector: Health Technology
Industry: Biotechnology
Country: Hong Kong SAR China
Exchange: HKEX
Shares outstanding: 75.06M
Employees: 85
ISIN: CNE100007NF2
Beta: -2.39

Technical view

Not enough data

Where the price sits against its 50- and 200-day moving averages.

Valuation & analysis

Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.

News

Yahoo FinanceJun 05, 2026

China's Leading Innovative Drug Developer for Allergic and Autoimmune Diseases LongBio Pharma Lists on Hong Kong Stock Exchange

LongBio Pharma, a portfolio company of Qiming Venture Partners and a leading innovative drug developer for allergic and autoimmune diseases in China, listed on the Hong Kong Stock Exchange on June 5, 2026 Beijing time, marking the seventh IPO for Qiming Venture Partners this year. LongBio Pharma (01779.HK) issued its shares at a price of HK$96.06 per share and opened at HK$144.30 per share with a market capitalization of HK$10.7 billion.

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.